Therapeutic Role of Antimicrobial Peptides in Diabetes Mellitus

Biologics (Basel, Switzerland) Pub Date : 2022-03-18 DOI:10.3390/biologics2010008

Julia Depta, P. Małkowska, M. Wysokińska, Karolina Todorska, Olga Sierawska, Rafał Hrynkiewicz, Dominika Bębnowska, P. Niedźwiedzka-Rystwej

{"title":"Therapeutic Role of Antimicrobial Peptides in Diabetes Mellitus","authors":"Julia Depta, P. Małkowska, M. Wysokińska, Karolina Todorska, Olga Sierawska, Rafał Hrynkiewicz, Dominika Bębnowska, P. Niedźwiedzka-Rystwej","doi":"10.3390/biologics2010008","DOIUrl":null,"url":null,"abstract":"Antimicrobial peptides (AMPs) have recently become widely publicized because they have the potential to function in alternative therapies as “natural” antibiotics, with their main advantage being a broad spectrum of activity. The potential for antimicrobial peptides to treat diabetes mellitus (DM) has been reported. In diabetes mellitus type I (T1D), cathelicidin-related antimicrobial peptide (CRAMP), cathelicidin antimicrobial peptide (CAMP) and mouse-β- defensin 14 (mBD14) are positively affected. Decreased levels of LL-37 and human neutrophil peptide 1-3 (HNP1-3) have been reported in diabetes mellitus type II (T2D) relative to healthy patients. Moreover, AMPs from amphibians and social wasps have antidiabetic effects. In infections occurring in patients with tuberculosis-diabetes or diabetic foot, granulysin, HNP1, HNP2, HNP3, human beta-defensin 2 (HBD2), and cathelicidins are responsible for pathogen clearance. An interesting alternative is also the use of modified M13 bacteriophages containing encapsulated AMPs genes or phagemids.","PeriodicalId":93526,"journal":{"name":"Biologics (Basel, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/biologics2010008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Antimicrobial peptides (AMPs) have recently become widely publicized because they have the potential to function in alternative therapies as “natural” antibiotics, with their main advantage being a broad spectrum of activity. The potential for antimicrobial peptides to treat diabetes mellitus (DM) has been reported. In diabetes mellitus type I (T1D), cathelicidin-related antimicrobial peptide (CRAMP), cathelicidin antimicrobial peptide (CAMP) and mouse-β- defensin 14 (mBD14) are positively affected. Decreased levels of LL-37 and human neutrophil peptide 1-3 (HNP1-3) have been reported in diabetes mellitus type II (T2D) relative to healthy patients. Moreover, AMPs from amphibians and social wasps have antidiabetic effects. In infections occurring in patients with tuberculosis-diabetes or diabetic foot, granulysin, HNP1, HNP2, HNP3, human beta-defensin 2 (HBD2), and cathelicidins are responsible for pathogen clearance. An interesting alternative is also the use of modified M13 bacteriophages containing encapsulated AMPs genes or phagemids.

查看原文本刊更多论文

抗菌肽在糖尿病中的治疗作用

抗菌肽（AMP）最近被广泛宣传，因为它们有潜力作为“天然”抗生素在替代疗法中发挥作用，其主要优势是具有广谱活性。抗菌肽治疗糖尿病（DM）的潜力已被报道。在I型糖尿病（T1D）中，组织蛋白酶相关抗菌肽（CRAMP）、组织蛋白酶抗菌肽（CAMP）和小鼠-β-防御素14（mBD14）受到积极影响。据报道，与健康患者相比，II型糖尿病（T2D）中LL-37和人中性粒细胞肽1-3（HNP1-3）的水平降低。此外，两栖动物和群居黄蜂的AMPs具有抗糖尿病作用。在结核性糖尿病或糖尿病足患者中发生的感染中，颗粒溶素、HNP1、HNP2、HNP3、人β-防御素2（HBD2）和组织蛋白酶负责病原体清除。一种有趣的替代方案也是使用含有封装的AMPs基因或噬菌体的修饰的M13噬菌体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biologics (Basel, Switzerland)

自引率

0.00%

发文量